Cancer clot prevention: is Once-a-Day pill as good as twice?
NCT ID NCT07005024
Summary
This study aims to find the safest and most effective way to use a common blood thinner (apixaban) to prevent dangerous blood clots in cancer patients. About 996 people with cancer who are at moderate risk for clots will be randomly assigned to take either a standard twice-daily dose, a new once-daily dose, or no blood thinner at all for six months. Researchers will track which group has fewer clots, serious bleeding events, or deaths to see if a simpler, once-daily dose works just as well.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.